FindTrial
Sign In

EFFECT OF AN ANTI-OXIDANT TREATMENT ON RESISTIN SERUM LEVELS. A RANDOMISED STUDY

EFFECT OF AN ANTI-OXIDANT TREATMENT ON RESISTIN SERUM LEVELS. A RANDOMISED STUDY

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002368-27-IT
Enrollment
Unknown
Registered
2005-07-01
Start date
2005-07-01
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Data suggesting participation of resistin, a new discovered protein, whose biological significance is still uncertain, in oxidative processes have been sporadically published. One is tempted to speculate that mononuclear blood cells would release this protein into the systemic circulation, where it acts as a buffer system, with some anti-oxidant mechanism. Consequently, a treatment with antioxidant substances (vitamin C) might reduce resistin levels. MedDRA version: 6.1 Level: PT Classification

Interventions

Trade Name: CEBION*500MG 20CPR MAST. Product Name: NA Product Code: NA Pharmaceutical Form: Chewable tablet INN or Proposed INN: Ascorbic acid (vit C) CAS Number: 50-81-7 Concentration unit: mg millig

Sponsors

AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026